このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Y-mAbs Therapeutics 将来の成長

Future 基準チェック /16

Y-mAbs Therapeuticsの収益は年間22.8%で減少すると予測されていますが、年間収益は年間16.4%で増加すると予測されています。EPS は年間減少すると予測されています。自己資本利益率は 3 年後に-4.3% 14.1%なると予測されています。

主要情報

-24.7%

収益成長率

-17.1%

EPS成長率

Biotechs 収益成長	24.2%
収益成長率	16.0%
将来の株主資本利益率	-4.3%
アナリストカバレッジ	Good
最終更新日	28 Jun 2024

今後の成長に関する最新情報

Recent updates

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12

業績と収益の成長予測

NasdaqGS:YMAB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	126	-64	N/A	-41	4
12/31/2025	117	-30	-31	-6	7
12/31/2024	96	-26	-33	-18	7
3/31/2024	84	-22	-18	-18	N/A
12/31/2023	85	-21	-27	-27	N/A
9/30/2023	93	-19	-28	-28	N/A
6/30/2023	85	-39	-46	-46	N/A
3/31/2023	75	-74	-64	-64	N/A
12/31/2022	65	-96	-76	-76	N/A
9/30/2022	43	-134	-102	-101	N/A
6/30/2022	40	-135	-100	-100	N/A
3/31/2022	40	-117	-96	-96	N/A
12/31/2021	35	-55	-104	-103	N/A
9/30/2021	46	-38	-87	-86	N/A
6/30/2021	37	-42	-93	-92	N/A
3/31/2021	26	-60	-102	-101	N/A
12/31/2020	21	-119	-91	-91	N/A
9/30/2020	N/A	-123	-99	-98	N/A
6/30/2020	N/A	-114	-97	-95	N/A
3/31/2020	N/A	-91	-84	-82	N/A
12/31/2019	N/A	-81	-75	-73	N/A
9/30/2019	N/A	-72	-63	-62	N/A
6/30/2019	N/A	-59	-51	-50	N/A
3/31/2019	N/A	-52	-48	-48	N/A
12/31/2018	N/A	-43	-41	-41	N/A
9/30/2018	N/A	-38	-34	-34	N/A
6/30/2018	N/A	-31	-28	-27	N/A
3/31/2018	N/A	-24	-19	-19	N/A
12/31/2017	N/A	-19	N/A	-16	N/A

アナリストによる今後の成長予測

収入対貯蓄率: YMAB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: YMAB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: YMAB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: YMABの収益 ( 16.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: YMABの収益 ( 16.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: YMAB 3 年以内に赤字になると予測されています。

Y-mAbs Therapeutics 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 42%

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Price target increased by 9.3% to US$13.67

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

Consensus EPS estimates upgraded to US$0.70 loss

Consensus revenue estimates increase by 27%

Recent updates

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Executive VP notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Announces New Interim Analysis of Phase 2 Data for Naxitamab At 2024 Asco Annual Meeting

Founder recently sold US$396k worth of stock

Founder notifies of intention to sell stock

Y-mAbs: There's A Ceiling Here Somewhere

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Y-mAbs Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Y-mAbs Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024

Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Consensus estimates of losses per share improve by 42%

Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Y-mAbs Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Price target increased by 9.3% to US$13.67

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Founder exercised options to buy US$370k worth of stock.

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$795k worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Y-mAbs Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023

Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma

Consensus EPS estimates upgraded to US$0.70 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil

Consensus revenue estimates increase by 27%

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Price target increased by 11% to US$10.50

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Updates Financial Guidance for the Full-Year 2023

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Consensus estimates of losses per share improve by 14%

Price target decreased by 15% to US$9.14

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Y-mAbs Therapeutics, Inc. and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

Rosen Law Firm Encourages Y-Mabs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Price target decreased to US$10.88

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Y-mAbs Therapeutics, Inc. Announces National Medical Products Administration in China Has Granted Danyelza 40Mg/10Ml Conditional Approval

Y-mAbs Therapeutics, Inc. Announces Complete Response Letter for Omburtamab Biologics License Application

Price target decreased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022

Y-mAbs Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Consensus EPS estimates fall by 18%

Y-mAbs Therapeutics Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

Y-mAbs Therapeutics, Inc Announces Pivotal Data for Omburtamab

Y-Mabs Therapeutics, Inc. Announces Scheduling of Fda Advisory Committee Meeting for Omburtamab

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

Consensus EPS estimates fall by 16%

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022